Menu Search
Equities

Alteco Medical AB

ALTE:AKT

Alteco Medical AB

Actions
  • Price (SEK)0.12
  • Today's Change0.00 / 0.00%
  • Shares traded1.15k
  • 1 Year change-69.70%
  • Beta--
Data delayed at least 15 minutes, as of Apr 17 2024 17:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Alteco Medical AB is a Sweden-based company engaged in the healthcare and biotechnology business sector. The Company develops medical devices focusing on intensive care. The Company’s product named Alteco LPS Adsorber is used within the sepsis area and reduces endotoxin (LPS) levels in blood and positive indications on sepsis markers. The product is used for patients with verified gram-negative sepsis caused by gastro-intestinal perforation, complications after abdominal surgery and uro-genital sepsis but patients with other sources of sepsis such as burns and complications after organ transplant could also respond to treatment. In addition, the Company provides various applications, including gram negative infection, abdominal sepsis, sepsis postoperatively or post trauma and lung originated sepsis, among others.

  • Revenue in -- (TTM)--
  • Net income in --
  • Incorporated--
  • Employees--
  • Location
    Alteco Medical ABHostbruksvagen 8LUND 226 60SwedenSWE
  • Phone+46 46328600
  • Fax+46 46148650
  • Websitehttps://altecomed.com/
More ▼

Institutional shareholders

0.06%Per cent of shares held by top holders
HolderShares% Held
Evli Fund Management Co. Ltd.as of 28 Mar 202435.13k0.06%
Data from 28 Mar 2024 - 28 Mar 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.